Fig. 1



6000
5000
4000
3000
2000
1000
0
Tumor volume (mm3±SD)
5
10
15
20
25
Elapsed days from transfer
Vehicle
Compound 1
Anti-PD-1 antibody
Anti-PD-1 antibody + Compound 1
*P<0.05
(Dunnett's test)
*
*

Fig. 2



* *
*
*
**P<0.01(τ-test)
* P<0.05
Ratio of effector memory T cell
(% CD8-positive T cell)
60
50
40
30
20
10
0
vehicle
Compound 1
Anti-PD-1 antibody
Anti-PD-1 antibody
+ Compound 1

Fig. 3




Fig. 4

Engraftment after re-transferred tumor

	Number of therapeutically-responsible subjects	Number of engraftment-acceptable subject after re-transfer
Compound 1	1／8	0／1
Anti-PD-1 antibody	1／8	1／1
Anti-PD-1 antibody + Compound 1	6／8	0／6

Fig. 5




*P<0.05
(Dunnetts's test)
Vehicle
Compound 1
Anti-CTLA-4 antibody
Anti-CTLA-4 antibody + Compound 1
Tumor volume (mm3 ± SD)
4000
3000
2000
1000
0
7
11
15
19
23
Elapsed days from transfer
*
*
*

Fig. 6


*P<0.05
(τ-test)
*
Ratio of effector memory T cell
(% CD8-positive T cell)
35
30
25
20
15
10
5
0
vehicle
Compound 1
Anti-CTLA-4 antibody
Anti-CTLA-4 antibody
+ Compound 1